



1645

PATENT

Docket No.: 19226/2081 (R-5661)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Balasubramanian et al.

Serial No. : 10/000,226

Cnfrm. No. : 9220

Filed : November 30, 2001

For : METHOD OF COMPLEXING A PROTEIN BY
THE USE OF A DISPERSED SYSTEM AND
PROTEINS THEREOF

Examiner:
Unknown

Art Unit:
1645

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97-1.98

U.S. Patent and Trademark Office
Box 2327
Arlington, Virginia 22202
Box:

RECEIVED

APR 29 2002

TECH CENTER 1600/2900

Dear Sir:


In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, applicants hereby bring to the attention of the United States Patent and Trademark Office, pursuant to 37 C.F.R. §§ 1.97-1.98, the enclosed documents listed on the attached PTO-1449 form.

Pursuant to 37 C.F.R. § 1.97(b), no fee is required. If additional fees are required, however, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 14-1138.

It is respectfully requested than an Examiner-initialed copy of this form be returned to the undersigned.


Respectfully submitted,

Date: April 22, 2002


Joseph M. Noto
Registration No. 32,163

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1601
Facsimile: (585) 263-1600

RS73908.1



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use several sheets if necessary)
(PTO-1449)

ATTY. DOCKET NO.

19226/2081 (R-5661)

APPLICANT

Balasubramanian et al.

FILING DATE

November 30, 2001

SERIAL NO.

10/000,226

GROUP ARF UNIT

1645

RECEIVED

APR 29 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	1	Balasubramanian et al., "Liposomes as Formulation Excipients for Protein Pharmaceuticals: A Model Protein Study," <u>Pharm. Res.</u> , 17(3):344-350 (2000)
	2	Tavio et al., "Human Chorionic Gonadotropin in the Treatment of HIV-Related Kaposi's Sarcoma," <u>Eur. J. Cancer</u> , 34(10):1634-1637 (1998)
	3	Lunardi-Iskandar et al., "Effects of a Urinary Factor From Women in Early Pregnancy on HIV-1, SIV and Associated Disease," <u>Nature Med.</u> , 4(4):428-434 (1998)
	4	Lee-Huang et al., "Lysozyme and RNases as Anti-HIV Components in β -core Preparations of Human Chorionic Gonadotropin," <u>Proc. Natl. Acad. Sci. USA</u> , 96:2678-2681 (1999)
	5	Timasheff et al., "Preferential Binding of Solvent Components to Proteins in Mixed Water-Organic Solvent Systems," <u>Biochem.</u> , 7(7):2501-2513 (1968)
	6	Rariy et al., "Protein Refolding in Predominantly Organic Media Markedly Enhanced by Common Salts," <u>Biotechnol. Bioeng.</u> , 62(6):704-710 (1999)
	7	Rariy et al., "Correct Protein Folding in Glycerol," <u>Proc. Natl. Acad. Sci. USA</u> , 94:13520-13523 (1997)
	8	Knubovets et al., "Structure, Thermostability, and Conformational Flexibility of Hen Egg-White Lysozyme Dissolved in Glycerol," <u>Proc. Natl. Acad. Sci. USA</u> , 96:1262-1267 (1999)
	9	Purohit et al., "Mutants of Human Choriogonadotropin Lacking N-Glycosyl Chains in the α -Subunit. 1. Mechanism for the Differential Action of the N-Linked Carbohydrates," <u>Biochem.</u> , 36:12355-12363 (1997)
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.	SERIAL NO.
	19226/2081 (R-5661)	10/000,226
	APPLICANT	
	Balasubramanian et al.	
	FILING DATE	GROUP ART UNIT
	November 30, 2001	1645

RECEIVED

APR 24 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	10	Balasubramanian et al., "Interferon- γ -Inhibitory Oligodeoxynucleotides Alter the Conformation of Interferon- γ ," <u>Molecular Pharmacol.</u> , 53:926-932 (1998)
	11	Aloj et al., "Interaction of I, 8-ANS With Human Luteinizing Hormones: A Probe for Subunit Interactions of hCG and hLH," <u>Arch. Biochem. Biophys.</u> , 165:478-479 (1973)
	12	Morozova et al., "Stability of Equine Lysozyme. I. Thermal Unfolding Behaviour," <u>Biophys. Chem.</u> , 41:185-191 (1991)
	13	Ikeguchi et al., "Evidence for Identity Between the Equilibrium Unfolding Intermediate and a Transient Folding Intermediate: A Comparative Study of the Folding Reactions of α -Lactalbumin and Lysozyme," <u>Biochem.</u> , 25:6965-6972 (1986)
	14	Luo et al., "The 28-111 Disulfide Bond Constrains the α -Lactalbumin Molten Globule and Weakens Its Cooperativity of Folding," <u>Proc. Natl. Acad. Sci. USA</u> , 96:11283-11287 (1999)
	15	Witzke et al., "Beta-Human Choriogonadotropin Therapy and HIV-Related Kaposi's Sarcoma," <u>Eur. J. Med. Res.</u> , 2:155-158 (1997)
	16	Lakowicz, <u>Principles of Fluorescence Spectroscopy, Second Edition</u> , New York, New York: Plenum Publishers, pp. 51-54 (1999)
	17	"Stability of Protein Pharmaceuticals: Part A: Chemical and Physical Pathways of Protein Degradation," in Ahern, eds., <u>Pharmaceutical Biotechnology</u> , Vol. 2, New York, New York: Plenum Press, pp. vii-xvii (1992)
	18	"Stability of Protein Pharmaceuticals: Part B: <i>In Vivo</i> Pathways of Degradation and Strategies for Protein Stabilization," in Ahern, eds., <u>Pharmaceutical Biotechnology</u> , Vol. 3, New York, New York: Plenum Press, pp. vii-viii (1992)
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		